M. Learoyd

发表

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.

D. Nicolau, T. Edeki, Shampa Das, 2015, The Journal of antimicrobial chemotherapy.

Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours

Bing-he Xu, Jianming Xu, J. Shentu, 2019, Cancer Chemotherapy and Pharmacology.

Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients

Diansong Zhou, H. Tomkinson, K. Bui, 2018, Clinical Pharmacokinetics.

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours

R. Plummer, A. Italiano, L. Dirix, 2018, Advances in Therapy.

Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)

Y. Bang, A. Italiano, S. Domchek, 2018 .

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.

F. Saad, C. Redfern, N. Clarke, 2018, The Lancet. Oncology.

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

M. Gore, Y. Drew, S. Domchek, 2018, Gynecologic Oncology.

Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

A. Tolcher, D. Gandara, Paul D. Smith, 2014, Clinical Cancer Research.

A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors.

A. Tolcher, K. Papadopoulos, A. Patnaik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations

Diansong Zhou, Venkatesh Pilla Reddy, Diansong Zhou, 2018, Clinical pharmacology and therapeutics.

An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.

T. Edeki, Jianguo Li, M. Sunzel, 2015, International journal of antimicrobial agents.

Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment

Myung Ah Lee, J. Blay, A. Ravaud, 2020, British journal of clinical pharmacology.

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

J. Schellens, M. Nicolson, S. Leijen, 2011, Cancer Chemotherapy and Pharmacology.

A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.

S. Aamdal, R. Kurzrock, I. Smith, 2013, European journal of cancer.

Efficacy and Safety Exposure‐Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients

Diansong Zhou, H. Tomkinson, K. Bui, 2019, Clinical pharmacology and therapeutics.

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors

G. Manikhas, S. Tjulandin, U. Keilholz, 2014, Investigational New Drugs.

Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers.

T. Edeki, M. R. Bouw, Shampa Das, 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

Ruey-min Lee, T. Bekaii-Saab, D. Sullivan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects

T. Edeki, Jianguo Li, Shampa Das, 2015, Pharmacology research & perspectives.

In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450

G. Scarfe, H. Swaisland, V. Reddy, 2018, Xenobiotica; the fate of foreign compounds in biological systems.

A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese Subjects

T. Edeki, Jianguo Li, M. Learoyd, 2016, Clinical Drug Investigation.